Solar Foods, a leading provider of sustainable protein solutions, has submitted a GRAS (Generally Recognised as Safe) notification to the United States Food and Drug Administration (FDA) for its product, Solein. The aim is to obtain a no questions letter, following the company’s previous self-affirmed GRAS status obtained in September 2024. This regulatory step is crucial for the company’s commercial activities in the US market. To achieve this, Solar Foods has provided necessary safety documentation for evaluation by the FDA. The process involves initial checks, scientific evaluation, and potential clarification inquiries by the FDA. The anticipated outcome is the issuance of a no questions letter, indicating the safety of Solein for its intended use. This achievement will further support Solar Foods’ expansion plans in the US and other markets demanding FDA approvals. Troels N rgaard, Chief Commercial Product Officer at Solar Foods, emphasized the significance of this regulatory milestone for Solein’s market prospects. Solar Foods’ innovative product, Solein, has already received novel food regulatory approval in Singapore, and the company is progressing towards obtaining similar approvals in the UK and EU markets. The ultimate goal is to establish Solein as the preferred environmentally friendly protein source globally. Solein’s unique production method, using air and electricity to grow a single microbe, sets it apart as a versatile and sustainable protein ingredient. Solar Foods, founded in 2017 and listed on the Nasdaq First North Growth Market Finland, is committed to revolutionizing protein production through its innovative approach without reliance on traditional agriculture. For more information about Solein and Solar Foods, visit their official website.
This article was automatically generated from an e-mail sent to the altii editorial system. Please note that the content has not been checked for accuracy, but we always endeavor to provide you with interesting and relevant information.